CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
ADHD medication +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00573859
NCT00573859Phase 2Completed

The Reinforcing Mechanisms of Smoking in Adult ADHD

University of California, Irvine·interventional·Posted Dec 14, 2007·Updated Nov 7, 2011

In Brief

A Phase 2 clinical trial evaluating ADHD medication and Placebo for ADHD. Completed, enrolled 27 participants across 1 site.

Detailed Summary

Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated. Smoking may be a form of self-medication in people with ADHD, which has specific reinforcing mechanisms such as improvement of ADHD core symptoms, enhancement of moods and arousal, or a combination of both. In addition, the reinforcing effects of smoking may be potentiated by stimulant medication. The study examined the reinforcing effects of ad libitum smoking with and without ADHD medication in adult smokers with clinically diagnosed ADHD. Participants were adults with ADHD. The effects of two day of ADHD medication compared to two days on placebo for were studied on nicotine intake (i.e., cotinine levels). In addition, task performance on the Continuous Performance Task and nicotine withdrawal symptoms were examined in response to ADHD medication + smoking a cigarette versus ADHD medication + abstinence versus placebo medication + smoking versus placebo medication + abstinence. The study identified the reinforcing mechanisms of smoking in interaction with ADHD medication. The findings will contribute to a better understanding of nicotine addiction and facilitate the development of targeted smoking cessation and prevention programs for individuals with ADHD and other people with deficiencies in impulse control and excessive risk taking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 14, 2007
Enrollment StartSep 1, 2006
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.6 years ago

Interventions

ADHD medicationdrug

For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.

Placebodrug

For the placebo condition, participants received placebo pills for two consecutive days.